Newborn Screening for X-Linked Adrenoleukodystrophy (X-ALD): Biochemical, Molecular, and Clinical Characteristics of Other Genetic Conditions
Genes · 2024
DOI: 10.3390/genes15070838 ↗Kurz gefasst
Fachartikel in der Zeitschrift Genes, 2024. Verfasst von Carlos F Mares Beltran und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Metabolic Disorders, Children's Hospital of Orange County (CHOC), Orange, CA 92868, USA. Hauptthemen laut MEDLINE: Adrenoleukodystrophy, Neonatal Screening, ATP Binding Cassette Transporter, Subfamily D, Member 1. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The state of California (CA) added X-linked adrenoleukodystrophy (X-ALD) to newborn screening (NBS) in 2016 via the measurement of C26:0-lysophosphatidylcholine (C26:0-LPC) in a two-tier fashion, followed by sequencing of the ABCD1 gene. This has resulted in the identification of individuals with genetic conditions beyond X-ALD that can also result in elevated C26:0-LPC by NBS. We describe the biochemical, molecular, and clinical characteristics of nine patients from two metabolic centers in California who screened positive by NBS for elevated C26:0-LPC between 2016 and 2022 and were ultimately diagnosed with a genetic condition other than X-ALD. Seven individuals were diagnosed with Zellweger spectrum disorder (ZSD) due to biallelic variants in PEX genes. One male was diagnosed with Klinefelter syndrome and one female was found to have an X chromosome contiguous gene deletion syndrome after the identification of a heterozygous VUS and hemizygous VUS variant in ABCD1, respectively. Patients with ZSD had significantly higher first- and second-tier C26:0-LPC levels compared to the two non-ZSD cases. Identification of children with ZSD and atypical patterns of ABCD1 variants is a secondary benefit of NBS for X-ALD, leading to earlier diagnosis, prompt therapeutic initiation, and more accurate genetic counseling. As screening for X-ALD continues via the measurement of C26:0-LPC, our knowledge of additional genetic conditions associated with elevated C26:0-LPC will continue to advance, allowing for increased recognition of other genetic disorders for which early intervention is warranted.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Metabolic Disorders, Children's Hospital of Orange County (CHOC), Orange, CA 92868, USA.
- Division of Medical Genetics, Albany Medical Center (AMC), Albany, NY 12208, USA.
- Division of Medical Genetics, Department of Pediatrics, Lucile Packard Children's Hospital, Stanford University, Stanford, CA 94304, USA.
ORCID-Profile: Carlos F Mares Beltran, Christina G Tise, Richard Chang
Zitieren
APA
Mares Beltran, C. F., Tise, C. G., Barrick, R., Niehaus, A. D., Sponberg, R., Chang, R., Enns, G. M., & Abdenur, J. E. (2024). Newborn Screening for X-Linked Adrenoleukodystrophy (X-ALD): Biochemical, Molecular, and Clinical Characteristics of Other Genetic Conditions. Genes. https://doi.org/10.3390/genes15070838
Vancouver
Mares Beltran CF, Tise CG, Barrick R, Niehaus AD, Sponberg R, Chang R, et al. Newborn Screening for X-Linked Adrenoleukodystrophy (X-ALD): Biochemical, Molecular, and Clinical Characteristics of Other Genetic Conditions. Genes. 2024. doi:10.3390/genes15070838
BibTeX
@article{MaresBeltran2024,
author = {Mares Beltran, Carlos F and Tise, Christina G and Barrick, Rebekah and Niehaus, Annie D and Sponberg, Rebecca and Chang, Richard and Enns, Gregory M and Abdenur, Jose E},
title = {Newborn Screening for X-Linked Adrenoleukodystrophy (X-ALD): Biochemical, Molecular, and Clinical Characteristics of Other Genetic Conditions},
journal = {Genes},
year = {2024},
doi = {10.3390/genes15070838}
}
EUVIMED